Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HEPION PHARMACEUTICALS, INC.

(HEPA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HEPION PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

11/30/2021 | 08:19am EST
Item 8.01 Other Events



On November 30, 2021, Hepion Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation for the Company's lead drug candidate, CRV431, for the treatment of NASH. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits





(d) Exhibits



  99.1         Hepion Pharmaceuticals, Inc. Press Release dated November 30,
             2021
104          Cover Page Interactive Data File. The cover page XBRL tags are
             embedded within the inline XBRL document.




                                      -2-

© Edgar Online, source Glimpses

All news about HEPION PHARMACEUTICALS, INC.
01/12HEPION PHARMACEUTICALS : Announces Death of Director, Thomas Adams - Form 8-K
PU
01/12HEPION PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statem..
AQ
01/12Hepion Pharmaceuticals Announces Death of Director, Thomas Adams
AQ
01/12Hepion Pharmaceuticals, Inc Announces Demise of Thomas Adams, Ph.D., Member of Its Boar..
CI
01/10HEPION PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
01/06HEPION PHARMACEUTICALS : Announces USAN Selection of “Rencofilstat” as Nonprop..
PU
01/06HEPION PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/06Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonpro..
GL
01/05Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Confer..
AQ
01/05Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference
GL
More news
Analyst Recommendations on HEPION PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2020 - - -
Net income 2020 -20,4 M - -
Net cash 2020 40,0 M - -
P/E ratio 2020 -1,04x
Yield 2020 -
Capitalization 80,0 M 80,0 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 13
Free-Float 99,9%
Chart HEPION PHARMACEUTICALS, INC.
Duration : Period :
Hepion Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HEPION PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 1,05 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Robert T. Foster President, Chief Executive Officer & Director
John T. Cavan Chief Financial Officer
Gary S. Jacob Chairman
Daren Ure Chief Scientific Officer
Todd Milton Hobbs Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
HEPION PHARMACEUTICALS, INC.-7.89%80
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-6.39%51 206
BIONTECH SE-39.28%37 805